Mankind Pharma Ltd
Mankind Pharma Ltd (MANKIND) is scheduled to report results on 26 Oct 2026. Mankind Pharma Ltd last reported results for the quarter ended Jun 2026, with sales of ₹4,031 crore and net profit of ₹574 crore. The stock last traded at ₹2,500, a market capitalisation of ₹1,03,259 crore, on a P/E of 48.4. Over the past 52 weeks the stock has ranged between ₹1,910 and ₹2,642. Figures are as of 6 Oct 2026 and are not real time.
Mankind Pharma Ltd share price and key metrics
- Current price
- ₹2,500
- Market cap
- ₹1,03,259 cr
- Stock P/E
- 48.4
- Book value
- ₹395
- ROE
- 13.1%
- ROCE
- 13.5%
- Dividend yield
- 0.04%
- 52w high / low
- 2642/1910
Metrics as of 6 Oct 2026. Not real time.
Track Mankind Pharma Ltd
Cruxal reads every Mankind Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Mankind Pharma Ltd growth and returns
- 10 Years
- %
- 5 Years
- 18%
- 3 Years
- 18%
- TTM
- 14%
- 10 Years
- %
- 5 Years
- 11%
- 3 Years
- 17%
- TTM
- 13%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 11%
- 1 Year
- 1%
- 10 Years
- %
- 5 Years
- 17%
- 3 Years
- 16%
- Last Year
- 13%
Mankind Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹4,031 cr, up 12.9% from ₹3,570 cr a year earlier. Net profit was ₹574 cr, up 29.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3,061 | 3,199 | 3,079 | 3,570 | 3,697 | 3,567 | 3,443 | 4,031 |
| Expenses | 2,214 | 2,383 | 2,396 | 2,724 | 2,776 | 2,648 | 2,513 | 2,974 |
| Operating profit | 847 | 816 | 683 | 847 | 921 | 919 | 930 | 1,056 |
| OPM % | 28% | 26% | 22% | 24% | 25% | 26% | 27% | 26% |
| Other income | 109 | 87 | 249 | 83 | 94 | -31 | 94 | 49 |
| Interest | 7 | 221 | 191 | 171 | 170 | 157 | 142 | 110 |
| Depreciation | 100 | 187 | 231 | 219 | 222 | 223 | 223 | 226 |
| Profit before tax | 849 | 495 | 511 | 540 | 624 | 509 | 659 | 769 |
| Tax % | 22% | 22% | 17% | 18% | 17% | 19% | 15% | 25% |
| Net profit | 659 | 385 | 425 | 445 | 520 | 414 | 559 | 574 |
| EPS (₹) | 16.31 | 9.22 | 10.20 | 10.62 | 12.39 | 9.90 | 13.43 | 13.75 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Mankind Pharma Ltd annual results
| ₹ crore | Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,334 | 5,865 | 6,214 | 7,782 | 8,749 | 10,260 | 12,207 | 14,278 | 14,738 |
| Operating profit | 586 | 1,438 | 1,649 | 1,991 | 1,902 | 2,517 | 3,026 | 3,625 | 3,827 |
| OPM % | 18% | 25% | 27% | 26% | 22% | 25% | 25% | 25% | 26% |
| Net profit | 445 | 1,056 | 1,293 | 1,453 | 1,310 | 1,942 | 2,011 | 1,938 | 2,068 |
| EPS (₹) | 219.33 | 25.72 | 31.59 | 35.78 | 32.00 | 47.75 | 48.26 | 46.34 | 49.47 |
TTM is the trailing twelve months to the most recent quarter.
Mankind Pharma Ltd balance sheet
| ₹ crore | Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 20 | 40 | 40 | 40 | 40 | 40 | 41 | 41 |
| Reserves | 2,035 | 3,445 | 4,682 | 6,115 | 7,395 | 9,323 | 14,291 | 16,259 |
| Borrowings | 0 | 131 | 241 | 873 | 170 | 207 | 8,511 | 6,312 |
| Other liabilities | 968 | 1,449 | 1,397 | 2,080 | 2,080 | 2,313 | 4,808 | 5,143 |
| Total liabilities | 3,022 | 5,065 | 6,360 | 9,108 | 9,686 | 11,883 | 27,652 | 27,755 |
| Fixed assets | 316 | 1,600 | 1,664 | 3,588 | 4,251 | 4,545 | 19,005 | 18,620 |
| CWIP | 47 | 317 | 372 | 701 | 550 | 282 | 826 | 1,128 |
| Investments | 959 | 829 | 1,512 | 1,109 | 1,346 | 2,568 | 2,042 | 1,985 |
| Other assets | 1,700 | 2,319 | 2,811 | 3,709 | 3,538 | 4,488 | 5,780 | 6,022 |
| Total assets | 3,022 | 5,065 | 6,360 | 9,108 | 9,686 | 11,883 | 27,652 | 27,755 |
As reported by the company. Total assets equal total liabilities by construction.
Mankind Pharma Ltd cash flow
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 1,070 | 1,137 | 920 | 1,813 | 2,152 | 2,413 | 3,121 |
| Cash from investing | -436 | -1,222 | -1,369 | -1,052 | -2,081 | -12,624 | -181 |
| Cash from financing | -531 | -8 | 605 | -740 | 5 | 10,233 | -2,953 |
| Net cash flow | 103 | -92 | 156 | 22 | 77 | 22 | -12 |
| Free cash flow | 853 | 826 | -1,423 | 987 | 1,771 | 1,895 | 2,387 |
| CFO / operating profit | 97% | 96% | 71% | 112% | 103% | 98% | 102% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Mankind Pharma Ltd operating ratios
| Per year | Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | — | — | 37% | 32% | 22% | 26% | 17% | 14% |
| Debtor days | 22 | 33 | 19 | 18 | 24 | 30 | 46 | 44 |
| Inventory days | 166 | 175 | 243 | 265 | 188 | 180 | 219 | 193 |
| Days payable | 71 | 145 | 137 | 162 | 126 | 90 | 119 | 121 |
| Cash conversion cycle | 117 | 63 | 125 | 121 | 86 | 120 | 146 | 117 |
| Working capital days | 56 | 30 | 32 | 24 | 39 | 53 | -28 | -40 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Mankind Pharma Ltd shareholding pattern
Promoters held 72.63% at Jun 2026, broadly unchanged since Jun 2025. FIIs 9.45% and DIIs 15.39%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 74.87% | 72.71% | 72.70% | 72.67% | 72.67% | 72.66% | 72.66% | 72.63% |
| FIIs | 12.37% | 13.34% | 12.92% | 13.07% | 12.83% | 11.34% | 10.24% | 9.45% |
| DIIs | 9.91% | 11.05% | 11.47% | 11.50% | 11.91% | 13.26% | 14.46% | 15.39% |
| Public | 2.86% | 2.89% | 2.89% | 2.75% | 2.57% | 2.75% | 2.63% | 2.53% |
| No. of shareholders | 1,63,854 | 1,71,281 | 1,80,597 | 1,79,549 | 1,70,347 | 1,77,539 | 1,77,606 | 1,66,715 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Mankind Pharma Ltd’s next results date?
Mankind Pharma Ltd’s next results are scheduled for 26 Oct 2026.
- Board meetingConsideration and approval of unaudited financial results for Q2 and H1 ended September 30, 2026
See the full results calendar for every Indian company reporting in the next 30 days.
Mankind Pharma Ltd corporate filings
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: Please find attached certificate under Regulation 74(5) of the SEBI (DP) Regulations…
Read the full analysis - Mankind Pharma schedules Board Meeting on October 26, 2026, to consider and approve Q2 FY2027 financial resultsBoard Meetinglow impact
Cruxal's analysis: Mankind Pharma Limited has announced a Board meeting scheduled for October 26, 2026, to…
Read the full analysis - Mankind Pharma's subsidiary Bharat Serums and Vaccines Limited initiates voluntary liquidation processCompany Updatelow impact
Cruxal's analysis: Mankind Pharma Limited has announced that its material wholly owned subsidiary, Bharat…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
Cruxal's analysis: Please find attached, the intimation of clsoure of the trading window.
Read the full analysis - Mankind Pharma Limited announces successful appointment of Independent Director via postal ballotAGM/EGMlow impact
Cruxal's analysis: Mankind Pharma Limited has successfully concluded its postal ballot process, with…
Read the full analysis - Mankind Pharma Ltd discloses ESG rating intimationCompany Updatelow impact
Cruxal's analysis: Mankind Pharma Ltd has submitted an intimation regarding its ESG (Environmental, Social…
Read the full analysis - Mankind Pharma Ltd announces participation in upcoming investor conferencesCompany Updatelow impact
Cruxal's analysis: Mankind Pharma has issued a routine intimation regarding its participation in upcoming…
Read the full analysis - Mankind Pharma initiates voluntary liquidation of wholly owned subsidiary Bharat Serums and Vaccines LimitedCompany Updatelow impact
Cruxal's analysis: Mankind Pharma has announced the commencement of the voluntary liquidation process for…
Read the full analysis - Mankind Pharma Ltd allots 49,112 equity shares under ESOP planCompany Updatelow impact
Cruxal's analysis: Mankind Pharma has announced the allotment of 49,112 equity shares to eligible employees…
Read the full analysis - Mankind Pharma completes divestment of wholly owned subsidiary Broadway Hospitality Services Private LimitedCompany Updatelow impact
Cruxal's analysis: Mankind Pharma has finalized the sale of its stake in its wholly owned subsidiary…
Read the full analysis - Mankind Pharma Limited announces cessation of Independent Director Bharat Anand due to completion of termCompany Updatelow impact
Cruxal's analysis: Mankind Pharma Limited has informed the stock exchanges that Mr. Bharat Anand has ceased…
Read the full analysis - Mankind Pharma initiates voluntary liquidation of Bharat Serums and Vaccines Limited (BSVL) to consolidate business operationsOthersmedium impact
Cruxal's analysis: Mankind Pharma Limited has announced the voluntary liquidation of its material…
Read the full analysis - Mankind Pharma Ltd discloses ESG rating intimationCompany Updatelow impact
Cruxal's analysis: Mankind Pharma has submitted an intimation regarding its ESG rating to the stock…
Read the full analysis - Mankind Pharma Ltd releases routine press release dated August 20, 2026Company Updatelow impact
Cruxal's analysis: Mankind Pharma has filed a press release dated August 20, 2026, under Regulation 30 of…
Read the full analysis - Mankind Pharma Ltd issues notice of Postal Ballot via newspaper advertisementCompany Updatelow impact
Cruxal's analysis: Mankind Pharma has published a newspaper advertisement regarding the notice of a Postal…
Read the full analysis - Mankind Pharma Limited initiates postal ballot for appointment of Mr. Anish Vanraj Bafna as Independent DirectorAGM/EGMlow impact
Cruxal's analysis: Mankind Pharma Limited has issued a postal ballot notice to seek shareholder approval for…
Read the full analysis - Mankind Pharma completes realignment of security cover for NCDs and releases pledged shares of Bharat Serums and Vaccines LimitedCompany Updatelow impact
Cruxal's analysis: Mankind Pharma has finalized the realignment of security cover for its Non-Convertible…
Read the full analysis - Mankind Pharma incorporates wholly owned subsidiary in the NetherlandsCompany Updatelow impact
Cruxal's analysis: Mankind Pharma Limited has officially completed the incorporation of its wholly owned…
Read the full analysis - Mankind Pharma appoints Anish Vanraj Bafna as Non-Executive Independent DirectorOtherslow impact
Cruxal's analysis: Mankind Pharma Limited has announced the appointment of Mr. Anish Vanraj Bafna as an…
Read the full analysis - Mankind Pharma Ltd announces participation in upcoming investor conferencesCompany Updatelow impact
Cruxal's analysis: Mankind Pharma has issued an intimation regarding its participation in scheduled investor…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.